First advanced cervical cancer immunotherapy approved by FDA

The first advanced cervical cancer immunotherapy approved by the U.S FDA, MSD, recently announced that the U.S FDA approved its heavy immunotherapy Keytruda (pembrolizumab) to treat patients with advanced cervical cancer, whose condition progresses after chemotherapy for recurrent or metastatic cervical cancer Keytruda is also the first approved anti-PD-1 treatment for advanced cervical cancer. From the survival point of view, the 5-year survival rate of early cervical cancer is not low, IA patients can survive as high as 93%, IB patients also have 80% (general cancer stage from early to late is i, ii, iii, iv, of which i, ii, iii and a and b However, as the disease enters an advanced stage, the survival rate of patients also plummets Once the disease develops iv, the survival rate of patients drops sharply to 15%-16%. As an immunotherapy, Keytruda has proven its therapeutic potential in a number of cancers, including melanoma, lung cancer, and head and neck cancer, According to Mercado. In a clinical trial called KEYNOTE-158, its therapeutic effect in cervical cancer was confirmed. 9-price HPV vaccine for people aged 27-45 years old has been accepted by the FDA, according to Sina Pharma, the U.S FDA has accepted the protocol application for supplementary biologics for the 9-price HPV vaccine GARDASIL9 under Mercado Currently, the 9-price HPV vaccine is widely available in people under 27 years of age. It is reported that the application seeks to expand the age-adaptation certificate approval of GARDASIL 9 for women and men aged 27 to 45 years, to prevent certain types of HPV caused by vaccine coverage of certain cancers and diseases The FDA has approved a priority review of the drug's BLA and has established a prescription drug use fee law (PDUFA) and a time limit for approval, with an expected decision to be announced on October 6, 2018. Kun Pharmaceutical Group's long-acting sugar-reducing drug Supalutide injection clinical trial was approved on June 13, Kun Pharmaceutical Group announced that its holding company Shanghai Yinno Pharmaceutical Technology Co., Ltd., Kunming Yinno Pharmaceutical Technology Co., Ltd received the Approval of the State Drug Administration on Supalu tide injection (size 1 ml:3 mg) of the Drug Clinical Trial Approval (2018L0256) and will soon carry out the relevant products of phase I clinical trial. According to public information, Supalutide is a human source GLP-1 receptor agonists developed by Yinno Pharmaceuticals with independent intellectual property rights, and its preclinical results show that Supalutide has a longer half-life compared to natural GLP-1 Supalutide stimulates insulin secretion by activating GLP-1 receptors in a blood sugar-dependent manner, while inhibiting the release of glucagon. Fosun Pharmaceutical Subsidiary Chongqing Pharmaceutical Scoilol Tablets through the conformity evaluation of generic drugs June 11, Fosun Pharmaceuticals announced that its subsidiary Chongqing Pharmaceutical Sini received the State Drug Administration issued the "drug supplementary application approval" on the alfa osteothelial alcohol tablets, the drug successfully passed the generic drug consistency evaluation. Afa esotalol tablets are mainly used to treat osteoporosis symptoms, improve chronic renal insufficiency, parathyroid function is low, anti-vitamin D rickets and so on In September 2017, Chongqing Pharmaceutical Friends applied to the State Drug Administration for the consistent evaluation of generic drugs and accepted them In FY2017, Chongqing Pharmaceutical Friends' sales in China were approximately RMB74 million.